Adjuvant bevacizumab: positive data from a negative trial
Mené sur 2 591 patientes atteintes d'un cancer du sein métastatique triplement négatif, cet essai multicentrique international de phase III évalue, du point de vue de la survie sans maladie invasive, l'ajout du bevacizumab à une chimiothérapie à base d'anthracycline et/ou de taxane
Although much progress has been made in the development of targeted therapies in breast cancer in the past few years, only bevacizumab is approved for triple-negative metastatic breast cancer. Findings from phase 3 studies have shown that bevacizumab-based therapy can increase progression-free survival, 1 as have the findings of a meta-analysis. 2 In that meta-analysis, 2 bevacizumab and chemotherapy improved progression-free survival compared with chemotherapy alone with a hazard ratio of 0·64 ...
The Lancet Oncology , commentaire, 2012